Straightforward synthesis of novel 1-(2'-α-O-D-glucopyranosyl ethyl) 2-arylbenzimidazoles

Article abstract of DOI:10.3390/molecules17089887

A series of novel 1-(2'-α-O-D-glucopyranosyl ethyl) 2-arylbenzimidazoles has been prepared via one-pot glycosylation of ethyl-1-(2'-hydroxyethyl)-2-arylbenzimidazole- 5-carboxylate derivatives. Synthesis of the 2-arylbenzimidazole aglycones from 4-fluoro-3- nitrobenzoic acid was accomplished in four high-yielding steps. The reduction and cyclocondensation steps for the aglycone synthesis proceeded efficiently under microwave irradiation to afford the appropriate benzimidazoles in excellent yields within 2-3 min. Glycosylation of the hydroxyethyl aglycones with the perbenzylated 1-hydroxyglucopyranose, pretreated with the Appel-Lee reagent, followed by catalytic hydrogenolysis delivered the desired 1-(2'-α-O-D- glucopyranosyl ethyl) 2-arylbenzimidazoles in a simple and straightforward manner.

Full text of DOI:10.3390/molecules17089887

Molecules 2012, 17, 9887-9899; doi:10.3390/molecules17089887
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Straightforward Synthesis of Novel 1-(2′-α-O-D-Glucopyranosyl
ethyl) 2-Arylbenzimidazoles
Natarajan Arumugam 1,†, Aisyah Saad Abdul Rahim 1,*, Shafida Abd Hamid 2 and
Hasnah Osman 3
1
School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia
2
Kulliyyah of Science, International Islamic University Malaysia (IIUM), Jalan Istana,
Bandar Indera Mahkota, 25200 Kuantan, Pahang, Malaysia
3
School of Chemical Sciences, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia
†
Current address: Department of Chemistry, College of Sciences, King Saud University,
Riyadh 11451, Saudi Arabia.
* Author to whom correspondence should be addressed; E-Mail: aisyah@usm.my;
Tel.: +60-4653-4094; Fax: +60-4657-0017.
Received: 27 June 2012; in revised form: 27 July 2012 / Accepted: 13 August 2012 /
Published: 17 August 2012
Abstract: A series of novel 1-(2′-α-O-D-glucopyranosyl ethyl) 2-arylbenzimidazoles has
been prepared via one-pot glycosylation of ethyl-1-(2'-hydroxyethyl)-2-arylbenzimidazole-
5-carboxylate derivatives. Synthesis of the 2-arylbenzimidazole aglycones from 4-fluoro-3-
nitrobenzoic acid was accomplished in four high-yielding steps. The reduction and
cyclocondensation steps for the aglycone synthesis proceeded efficiently under microwave
irradiation to afford the appropriate benzimidazoles in excellent yields within 2–3 min.
Glycosylation of the hydroxyethyl aglycones with the perbenzylated 1-hydroxy-
glucopyranose, pretreated with the Appel-Lee reagent, followed by catalytic
hydrogenolysis delivered the desired 1-(2′-α-O-D-glucopyranosyl ethyl) 2-aryl-
benzimidazoles in a simple and straightforward manner.
Keywords:
2-arylbenzimidazole;
microwave-assisted
synthesis;
α-glycoside;
glycosylation; glycomimetic

Molecules 2012, 17
9888
1. Introduction
Carbohydrate-protein interactions on cell surfaces mediate important biological processes and
disease states, including cancer metastasis, inflammation, pathogenicity and Alzheimer’s disease [1–7].
Participating in such interactions are α-glycoside epitopes, found on bacteria, e.g., Mycoplasma, and
on numerous mammalian oligosaccharides, for instance sialyl Lewis X (sLex). The synthesis of
oligosaccharide ligands as potential inhibitors, however, remains laboriously demanding [8–10].
Alternatively, these oligosaccharides can be simplified by retaining functional groups essential for
key binding interactions and replacing the unwanted parts with heterocyclic scaffolds. This
simplification strategy has led to the emergence of pharmaceutically relevant glycomimetics as potent
inhibitors against new carbohydrate-based disease targets [8,9,11,12]. In recent years, considerable
synthetic efforts were devoted to the preparation of glycosyl-modified heterocycles as sLex
glycomimetics designed to inhibit selectin involvement in cancer metastasis and inflammation [4,5,9,11].
Additionally, several pyranosyl benzothiazoles and benzimidazoles have been found to inhibit
α-glycosidases and glycogen phosphorylases, which are promising targets for treatment of diabetes
mellitus [13–16].
Benzimidazoles are important heterocycles in medicinal chemistry with established clinical
examples including the proton pump inhibitor omeprazole [17] and the antihelmintic
albendazole [18,19]. Additionally, 1,2-difunctionalised benzimidazoles have shown diverse biological
activities as antagonists against prostaglandin D2 [20] and angiotensin II receptors [21]. They have
been prepared as guanine biomimetics that selectively suppress angiogenesis in vitro and in vivo [22].
Due to their biological significance, we became interested in the synthesis of substituted
2-arylbenzimidazoles as potential anti-infective and anti-proliferative agents.
Recently, however, we encountered persistent problems with the solubility of such compounds
during routine biological screening. To circumvent this solubility problem, we reasoned that by linking
a sugar moiety to the 2-arylbenzimidazoles via a hydroxyethyl linker, not only could the sugar moiety
modulate the solubility of the 2-arylbenzimidazoles, but it might also elicit novel pharmacological
effects as an α-O-glycoside [12,23–25]. Furthermore, to the best of our knowledge, these α-O-glucosyl
arylbenzimidazoles has not yet been reported. Thus, in this paper we describe, for the first time, a
straightforward synthesis of novel 1-(2′-α-O-D-glucopyranosyl ethyl) 2-arylbenzimidazoles via
one-pot glycosylation of hydroxyethyl arylbenzimidazole aglycones and 2,3,4,6-tetra-O-benzyl
1-hydroxylglucose employing the Appel-Lee reagent [26,27].
2. Results and Discussion
Our synthetic work started with esterification of the inexpensive precursor, 4-fluoro-3-nitrobenzoic
acid (1). Treatment of the ester with 2-aminoethanol gave the amino intermediate 2. Attempted
reduction of the aromatic nitro group by refluxing with ammonium formate and 10% Pd/C for 3 h
afforded the diamine 3 [28] in a modest 60% yield. After optimisation, microwave irradiation of the
same reaction mixture at 100 °C for 2 min afforded 3 in a much improved 85% yield (Scheme 1).

Molecules 2012, 17
9889
Scheme 1. Synthesis of benzimidazole aglycones 6a–d.
Reagents and Conditions: (i) H2SO4/EtOH, reflux, 75%; (ii) 2-aminoethanol, DIPEA, RT, ON,
89%; (iii) HCOONH4, Pd/C, MW, 2 min, 85%; (iv) MW, DMF, 2–3 min, 82–94%.
This diamine was found to be stable at room temperature, unlike other alkylated phenylenediamine
derivatives that we had prepared previously; these turned brown and decomposed, even when stored at
5–10 °C. The stability of the amino derivative 3 was possibly due to intramolecular hydrogen bonding
between the OH and NH2 groups, as apparent from single X-ray crystallographic analysis (Figure 1) [28].
Figure 1. ORTEP digram of 3 (CCDC 788495).
Next we turned our attention to the synthesis of 2-arylbenzimidazoles 6a–d. These are typically
prepared via condensation reactions of phenylenediamines with the corresponding acids or
aldehydes [29,30]. Harsh, dehydrating conditions are often a requisite in cyclocondensation reactions
with aromatic acids. More facile condensations can be achieved via arylaldehydes by employing
oxidative reagents, such as Cu(OAc)2, air, 1,4-benzoquinone, I2/KI and sodium metabisulfite [29,31–33].
After taking into consideration previous reports and the availability of commercial benzaldehydes,
we initially attempted the cyclocondensation with the diamine 3, aromatic aldehydes and sodium
metabisulfite in one pot as reported by Navarrete-Vázquez et al. [33] under conventional heating
conditions. The one-pot cyclocondensation failed to afford the benzimidazole products. Upon heating
under microwave conditions, the same reaction gave multiple spots on TLC, but we were unable to
isolate the desired benzimidazoles. Due to the unsuccessful attempts at the one-pot cyclocondensation

Molecules 2012, 17
9890
reaction, we then decided to react the diamine 3 with the metabisulfite adducts of arylaldehydes
5a–d [33,34]. The conventional reaction conditions (refluxing in DMF) initially suffered from long
reaction times and afforded only moderate yields of the desired benzimidazoles 6a–d. When the same
reactions were performed under optimised microwave conditions [33,35], the benzimidazole aglycones
6a–d were obtained in excellent 82–94% yields within 2–3 min (Table 1) using minimal solvent
(0.5–1 mL). Our results show that using microwaves as a heating source not only improves yields of
the desired benzimidazoles, but it also brings about tremendous reductions in reaction times and the
amount of solvent required.
Table 1. Influence of microwave irradiation and conventional heating on the synthesis of
benzimidazole derivatives 6a–d.
Conventional heating
Microwave heating
Time (min) Yield (%)
88
Entry
Products
R
Time (h)
Yield (%)
1
2
3
4
6a
6b
6c
6d
H
3.5
3
62
65
67
60
3
o-CH3
p-CH3
p-OCH3
2.5
2
82
94
89
2.5
3
2
1
The H-NMR spectrum of benzimidazole 6c showed the loss of the broad singlet NH2 peak at δ
4.60–4.85, which corroborates with the formation of the imine (C=N) that resonated at δ 156.1 in the
13C-NMR spectrum. High resolution mass spectrometry data revealed a peak at m/z = 325.1549
(M+H requires 325.1547), which corresponds to 6c. Single crystal X-ray analysis [36] confirmed
the structure of 2c (Figure 2). Arylbenzimidazoles derivatives 6a, 6b and 6d showed similar
spectroscopic patterns.
Figure 2. ORTEP digram of 6c (CCDC 786546).
With the alcohols 6a–d in hand, we next required a suitable glycosylation method to furnish the
α-O-glycosyl benzimidazoles in a facile manner. Derivatives of α-O-glycosides can be accessed in a

Molecules 2012, 17
9891
number of ways [37,38], one of the most efficient being the established in situ anomerisation
procedure which employs a 1-bromo sugar as the glycosyl donor. The tedious and costly preparation of
glycosyl bromides coupled with the corrosive nature of HBr gas prompted the search for alternative
methods to generate the desired bromides in situ. Several one-pot reactions were reported to furnish
glucosyl [39], galactosyl [40] and fucosyl [41] intermediates in moderate to good yields. Recently,
Shingu et al. described a practical one pot α-glycosylation method based on the Appel-Lee reaction
utilizing PPh3 and CBr4 [23,42].
Motivated by these findings, we attempted the glycosylation of the alcohols 6a–d by pre-treating
commercially available 2,3,4,6-tetra-O-benzyl-D-glucopyranose (7) with the Appel-Lee reagents for
3 h. This resulted in the in situ formation of glycosyl bromide, which underwent glycosylation with the
alcohols 6a–d after a further 24 h. This one-pot glycosylation step yielded the perbenzylated
α-O-glucosyl benzimidazoles 8a–d in 70–73% yields. Finally, catalytic hydrogenolysis step afforded
the target hydroxyl sugars 9a–d (Scheme 2).
Scheme 2. Synthesis of α-O-glucosyl benzimidazoles 9a–d.
Reactions and Conditions: (i) CBr4, PPh3, CH2Cl2, 3 h, followed by DIPEA, 24 h, 70–73%; (ii) H2,
Pd/C, 48 h, 62–66%.
Via the optimised conditions, the glycosylated products were obtained as a mixture of α:β anomers
(95:5), which is comparable to the ratios reported by Shingu [42]. The 1H-NMR of the isolated anomer
8c showed the α-proton appearing at δ 4.60 as a doublet (J = 3.3 Hz). This small J value strongly
indicated the successful formation of the desired α-O-glycosidic linkage between the glucopyranoside
moiety and 2'-hydroxyethyl 2-arylbenzimidazole scaffold. Further confirmation came from the
1H-NMR spectrum and HRMS of the deprotected sugar 9c. Absence of benzylic protons in 9c revealed
the characteristic α-proton (δ 4.61–4.68), and the HRMS showed the molecular peak at 487.2077
(M+H requires 487.2075) corresponding to the hydroxyl sugar 9c. The structures of the remaining
α-O-glucosylated arylbenzimidazole derivatives were established spectroscopically and corroborated
with 8c and 9c.

Molecules 2012, 17
9892
3. Experimental
3.1. General
1
13
All H- and C-NMR spectra were recorded on Bruker 300 and 400 MHz instruments in CDCl3
and DMSO-d6. High resolution mass spectrometry (HRMS) measurements of the benzimidazole
derivatives were acquired on an Agilent 6520 Quadrupole Time of Flight Mass Spectrometer (Agilent
Technologies, Santa Clara, CA, USA) operating in the MS mode. Microwave-assisted syntheses were
performed in CEM Discover™ microwave synthesizer. Melting points were measured on a Stuart
SMP10 instrument and are uncorrected. Preparative thin layer chromatography (PLC) was performed
using Merck 60 GF254 silica gel coated (1 mm) on glass plates (20 × 20 cm). TLC experiments were
performed on alumina-backed silica gel 40 F254 plates (Merck, Darmstadt, Germany). Visualisation of
TLC plates was performed under UV light and aided by KMnO4, iodine staining and 2% H2SO4 in
EtOH (charcoal staining for sugar). All commercially available starting materials and solvents are from
Sigma Aldrich, Acros and Merck; they were used without further purification.
Synthesis of ethyl 3-amino-4-(2-hydroxyethylamino)benzoate (3). A solution of 4-fluoro-3-nitrobenzoic
(1, 10 g, 0.054 mol) was refluxed in EtOH (100 mL) and conc. H2SO4 (4 mL) for 8 h. After completion
of reaction, evidenced by TLC analysis, the excess solvent was removed under reduced pressure.
The aqueous layer was extracted with EtOAc (50 × 2 mL). Upon washing with 10% NaHCO3
(100 mL), the combined organic layer was dried over Na2SO4 and concentrated. Crystallisation of the
crude product with hot hexane yielded the desired ethyl ester as colourless crystals (8.6 g). A portion
of the benzoate (2.0 g, 9.2 mmol) in dichloromethane (25 mL) was added to a solution of ethanolamine
(0.687 g, 14.0 mmol) and DIPEA (1.45 g, ~2 mL, 11.2 mmol) in dichloromethane (25 mL). The
reaction mixture was stirred overnight at room temperature, then washed with water (20 mL × 2) and
10% Na2CO3 (20 mL × 2). The dichloromethane layer was collected, dried over Na2SO4 and removed
under reduced pressure to afford the amino compound 2 (2.07 g, 89%). The amine 2 was used in the
next step without purification, thus to a solution of the amine 2 (500 mg, 1.96 mmol) in EtOH (4 mL)
was added HCOONH4 (430 mg, 6.82 mmol) and 10% Pd/C (250 mg, 2.34 mmol). The reaction
mixture was irradiated using a CEM Discover microwave synthesizer for 2 min at 100 °C. After
completion, the mixture was filtered through a bed of Celite and the filtrate evaporated under reduced
1
pressure to afford the title product 3 as white crystals (0.45 g, 85%). Mp 116–118 °C; H-NMR
(DMSO-d6, 300 MHz): δ 1.26 (t, J = 6.3 Hz, CH3, 3H), 3.16–3.21 (m, CH2, 2H), 3.61–3.69 (m, CH2,
2H), 4.18 (q, J = 7.2 Hz, OCH2, 2H), 4.73 (br s, NH2, 2H), 5.17–5.21 (m, NH, 1H), 6.46 (d, J = 8.1 Hz,
13
1H), 7.18–7.24 (m, 2H) ppm. C-NMR (DMSO-d6, 75 MHz): δ 15.3, 46.3, 60.1, 60.3, 108.7, 117.7,
134.9, 141.5, 167.2 ppm. ESI-MS m/z 225.2 (M+1). CCDC 788495 contains the supplementary
crystallographic data for structure 3.
3.2. General Procedure for the Microwave-Assisted Synthesis of Benzimidazoles 6a–d
The metabisulfite adduct 5 (2.0 eq.) was added to a solution of 3-amino-4-(2-hydroxyethylamino)
benzoate (3, 1.0 eq.) in DMF (0.5–1 mL). The reaction mixture was heated under microwave
conditions at 130 °C for 2 min. After completion, the mixture was diluted with EtOAc (10 mL) and

Molecules 2012, 17
9893
washed with H2O (10 mL). The organic layer was collected, dried over Na2SO4 and evaporated
in vacuo to yield a crude residue, which was recrystallised from EtOAc to afford the desired
benzimidazole as colourless crystals.
Ethyl 2-phenyl-1-(2-hydroxyethyl)-1H-benzimidazole-5-carboxylate (6a). Colourless crystals (0.97 g,
1
88%). Mp 123–125 °C; IR (KBr) 3400, 1637, 1265, 740 cm–1; H-NMR (CDCl3, 300 MHz): δ 1.46
(t, CH3, 3H), 4.15–4.29 (m, 2CH2, 4H), 4.41 (q, CH2, 2H), 6.05–6.18 (s, 1H), 7.20–7.84 (m, 8H) ppm.
13C-NMR (CDCl3, 75 MHz): δ 14.8, 47.5, 60.7, 61.2, 110.0, 121.4, 124.3, 125.1, 128.8, 129.0, 130.2,
130.4, 138.3, 141.6, 156.1, 167.1 ppm. HRMS (ESI/Q-TOF): m/z calcd for C18H18N2O3 (M+H),
311.1390; found 311.1391.
Ethyl 1-(2-hydroxyethyl)-2-o-tolyl-1H-benzimidazole-5-carboxylate (6b). White crystals (0.35 g, 82%).
1
Mp 119–121 °C; IR (KBr) 3398, 1641, 1273, 752 cm–1; H-NMR (CDCl3, 300 MHz): δ 1.41 (t, CH3,
3H), 2.12 (s, CH3, 3H), 3.69 (t, J = 5.7 Hz, CH2, 2H), 4.04 (t, J = 5.7 Hz, CH2, 2H), 4.39 (q, CH2, 2H),
13
7.17–7.42 (m, 5H), 7.92–7.95 (dd, J = 8.5, 1.6 Hz, 1H), 8.38 (d, J = 1.2 Hz, 1H) ppm. C-NMR
(CDCl3, 75 MHz): δ 14.4, 19.6, 46.6, 60.3, 61.0, 110.2, 121.7, 124.2, 124.7, 125.7, 129.2, 130.1,
130.2, 130.5, 137.9, 138.0, 142.0, 155.3, 167.2 ppm. HRMS (ESI/Q-TOF): m/z calcd for C19H20N2O3
(M+H), 325.1547; found 325.1548.
Ethyl 1-(2-hydroxyethyl)-2-p-tolyl-1H-benzimidazole-5-carboxylate (6c). Colourless crystals (1.0 g,
94%). Mp 138–140 °C; IR (KBr) 3377, 1639, 1275, 749 cm–1; 1H-NMR (CDCl3, 300 MHz): δ 1.47 (t,
J = 7.2 Hz, CH3, 3H), 2.38 (s, CH3, 3H), 4.18–4.30 (m, 2CH2, 4H), 4.41 (q, J = 7.2 Hz, OCH2, 2H),
6.25–6.40 (s, 1H), 7.00 (d, J = 8.1 Hz, 2H), 7.21 (d, J = 8.4 Hz, 1H), 7.59 (d, J = 8.1 Hz, 2H), 7.71 (d,
13
J = 8.7 Hz, 1H), 7.78 (s, 1H) ppm. C-NMR (CDCl3, 75 MHz): δ 14.8, 21.8, 47.5, 60.7, 61.2, 109.9,
121.2, 124.1, 125.0, 126.1, 129.4, 130.3, 138.3, 140.2, 141.5, 156.1, 167.0 ppm. HRMS (ESI/Q-TOF):
m/z calcd for C19H20N2O3 (M+H), 325.1547; found 325.1549. CCDC 786546 contains the
supplementary crystallographic data for structure 6c.
Ethyl 1-(2-hydroxyethyl)-2-(4-methoxyphenyl)-1H-benzimidazole-5-carboxylate (6d). Colourless
1
crystals (0.94 g, 89%). Mp 120–122 °C; IR (KBr) 3402, 1642, 1265, 740 cm–1; H-NMR (CDCl3,
300 MHz): δ 1.47 (t, CH3, 3H), 3.83 (s, OCH3, 3H), 4.22–4.30 (m, 2CH2, 4H), 4.41 (q, CH2, 2H), 6.71
(d, J = 9.0 Hz, 2H), 7.19 (d, J = 8.4 Hz, 1H), 7.67–7.73 (m, 4H) ppm. 13C-NMR (CDCl3, 75 MHz): δ
14.9, 47.5, 55.6, 60.7, 61.2, 109.7, 114.1, 121.0, 121.2, 124.0, 125.0, 132.0, 138.1, 141.4, 156.0, 161.1,
167.0 ppm. HRMS (ESI/Q-TOF): m/z calcd for C19H20N2O4 (M+H), 341.1496; found 341.1499.
3.3. General Procedure for the Synthesis of 1-(2′-α-O-D-glucopyranosyl ethyl) 2-arylbenzimidazoles 8a–d
A solution of 2,3,4,6-tetra-O-benzyl-D-glucopyranose (7, 1.0 eq.), PPh3 (3.0 eq.) and CBr4 (3.0 eq.)
in CH2Cl2 (3 mL) was stirred for 3 h under N2 atmosphere at room temperature. Upon completion of
reaction as evidenced by TLC analysis, a solution of DIPEA (2.5 eq.) followed by substituted
benzimidazole 6 (3.0 eq.) were added to the reaction mixture, which was stirred at room temperature
under N2 atmosphere for a further 24 h. The crude reaction mixture was purified by column
chromatography using EtOAc-hexanes (3:7) to afford the product as a semi-solid.

Molecules 2012, 17
9894
Ethyl 1-[2′-α-O-D-(2,3,4,6-tetra-O-benzylglucopyranosyl)ethyl]-2-phenyl-1H-benzimidazole-5-carboxylate
1
(8a). Isolated as low melting solid (0.27 g, 70%). IR (film) 3409, 1611, 1265, 740 cm–1; H-NMR
(CDCl3, 300 MHz): δ 1.44 (t, CH3, 3H), 3.23–3.30 (m, H-2), 3.32–3.36 (m, H-4), 3.46–3.51 (m, CH2,
2H), 3.54–3.60 (m, H-6a), 3.68–3.73 (m, H-6b), 3.76–3.82 (m, H-5), 3.98–4.06 (m, H-3), 4.37–4.41 (m,
CH2, 2H), 4.42–4.45 (m, CH2, 2H), 4.59 (d, J = 3.3 Hz, H-1), 4.46–4.94 (m, PhCH2, 8H), 7.11–8.59
13
(m, Ar-H, 28H) ppm. C-NMR (CDCl3, 75 MHz): δ 14.3, 44.6, 60.8, 65.9, 68.2, 70.5, 73.3, 73.4,
74.7, 75.7, 76.6, 79.8, 81.7, 97.6, 110.2, 122.2, 124.4, 124.8, 127.6, 127.7, 127.8, 127.9, 128.0, 128.3,
128.4, 128.8, 129.1, 129.2, 129.8, 130.1, 138.2, 138.2, 142.6, 155.8, 167.0 ppm. HRMS (ESI/Q-TOF):
m/z calcd for C52H52N2O8 (M+H), 833.3797; found 833.3799.
Ethyl 1-[2'-α-O-D-(2,3,4,6-tetra-O-benzylglucopyranosyl)ethyl]-2-o-tolyl-1H-benzimidazole-5-carboxylate
(8b). Isolated as low melting solid (0.20 g, 73%). IR (film) 3408, 1621, 1266 cm–1; 1H-NMR (CDCl3,
300 MHz): δ 1.41 (t, CH3, 3H), 2.23 (s, CH3, 3H), 3.23–3.30 (m, H-2), 3.35–3.39 (m, H-4), 3.45–3.49
(m, CH2, 2H), 3.51–3.61 (m, H-6a), 3.76–3.80 (m, H-6b), 3.81–3.87 (m, H-5), 4.18–4.25 (m, H-3),
4.27–4.37 (m, CH2, 2H), 4.38–4.44 (m, CH2, 2H), 4.53 (d, J = 3.3 Hz, H-1), 4.46–4.97 (m, PhCH2,
8H), 7.10–8.58 (m, 27H) ppm. 13C-NMR (CDCl3, 75 MHz): δ 14.8, 20.1, 44.3, 61.2, 66.5, 68.7, 71.0,
73.7, 73.8, 75.2, 76.1, 80.2, 82.1, 98.1, 110.7, 122.7, 124.7, 125.3, 126.3, 128.0, 128.1, 128.2, 128.3,
128.4, 128.7, 128.8, 129.9, 130.6, 130.9, 138.1, 138.3, 138.5, 138.6, 139.1, 143.1, 155.6, 167.4 ppm.
HRMS (ESI/Q-TOF): m/z calcd for C53H54N2O8 (M+H), 847.3953; found 847.3953.
Ethyl 1-[2′-α-O-D-(2,3,4,6-tetra-O-benzylglucopyranosyl)ethyl]-2-p-tolyl-1H-benzimidazole-5-carboxylate
1
(8c). Isolated as low melting solid (0.17 g, 72%). IR (film) 3392, 1645, 1261, 750 cm–1; H-NMR
(CDCl3, 300 MHz): δ 1.41 (t, J = 7.1 Hz, CH3, 3H), 2.42 (s, CH3, 3H), 3.24–3.31 (m, H-2, 1H),
3.32–3.38 (m, H-4, 1H), 3.47–3.50 (m, CH2, 2H), 3.51–3.55 (m, H-6a, 1H), 3.65–3.73 (m, H-6b, 1H),
3.75–3.82 (m, H-5, 1H), 3.98–4.05 (m, H-3, 1H), 4.37–4.39 (m, CH2, 2H), 4.40–4.44 (m, CH2, 2H),
4.60 (d, J = 3.3 Hz, H-1, 1H), 4.45–4.94 (m, PhCH2, 8H), 7.10–7.35 (m, Ar-H, 22H), 7.54 (d,
J = 8.7 Hz, 1H), 7.74 (d, J = 8.1 Hz, 2H), 8.04–8.08 (dd, J = 8.1, 1.5 Hz, 1H), 8.57 (d, J = 1.5 Hz, 1H)
13
ppm. C-NMR (CDCl3, 75 MHz): δ 14.8, 21.9, 45.0, 61.3, 66.4, 68.6, 70.9, 73.6, 73.7, 73.8, 75.2,
76.1, 80.2, 82.1, 98.0, 110.6, 122.6, 124.7, 125.5, 127.2, 128.0, 128.1, 128.2, 128.3, 128.4, 128.7,
128.8, 129.9, 130.0, 138.1, 138.3, 138.6, 139.1, 139.3, 140.7, 143.0, 156.4, 167.5 ppm. HRMS
(ESI/Q-TOF): m/z calcd for C53H54N2O8 (M+H), 847.3953; found 847.3953.
Ethyl 1-[2'-α-O-D-(2,3,4,6-tetra-O-benzylglucopyranosyl)ethyl]-2-p-methoxyphenyl-1H-benzimidazole-
5-carboxylate (8d). Isolated as low melting solid (0.28 g, 71%). IR (film) 3421, 1630, 1265, 740 cm–1;
1H-NMR (CDCl3, 300 MHz): δ 1.40 (t, CH3, 3H), 3.24–3.30 (m, H-2), 3.32–3.36 (m, H-4), 3.46–3.48
(m, CH2, 2H), 3.49–3.54 (m, H-6a), 3.70–3.78 (m, H-6b), 3.81 (s, OCH3, 3H), 3.82–3.84 (m, H-5),
3.98–4.04 (m, H-3), 4.35–4.39 (m, CH2, 2H), 4.40–4.43 (m, CH2, 2H), 4.60 (d, J = 3.6 Hz, H-1),
4.46–4.92 (m, PhCH2, 8H), 6.98 (d, J = 8.7 Hz, 2H), 7.10–7.33 (m, 20H), 7.51 (d, J = 8.4 Hz, 1H),
13
7.80 (d, J = 9 Hz, 2H), 8.01–8.05 (dd, J = 1.5, 8.4 Hz, 1H), 8.54 (d, J = 1.5 Hz, 1H) ppm. C-NMR
(CDCl3, 75 MHz): δ 14.8, 45.0, 55.7, 61.2, 66.3, 68.6, 70.9, 73.7, 73.8, 75.2, 76.1, 80.3, 82.2, 98.0,
110.4, 114.7, 122.4, 124.6, 125.5, 127.9, 128.0, 128.1, 128.2, 128.3, 128.4, 128.7, 128.8, 131.7, 138.1,

Molecules 2012, 17
9895
138.6, 139.1, 139.4, 143.0, 156.2, 161.5, 167.5 ppm. HRMS (ESI/Q-TOF): m/z calcd for C19H20N2O3
(M+H), 863.3902; found 863.3901.
3.4. General Procedure for the Catalytic Hydrogenolysis
A solution of perbenzylated glucopyranosyl arylbenzimidazole 8 (200 mg, 0.23 mmol) in MeOH
(10 mL) was hydrogenated in the presence of 10% Pd/C (100 mg, 0.93 mmol) at room temperature for
48 h. The reaction mixture was filtered through a bed of Celite and washed with MeOH (10 mL × 3).
The solvent was removed in vacuo to afford a crude residue which was purified by column
chromatography in CHCl3–MeOH (9:1) to give the desired product as a light yellow semisolid.
Ethyl 1-[2'-α-O-D-glucopyranosyl ethyl]-2-phenyl-1H-benzimidazole-5-carboxylate (9a). Isolated as
light yellow semisolid (0.14 g, 62%). IR (film) 3411, 1635, 1275, 750 cm–1; 1H-NMR (CDCl3, 300 MHz):
δ 1.34 (t, CH3, 3H), 2.64 (d, J = 9.3 Hz, H-4), 3.15 (d, J = 8.1 Hz, H-2), 3.24–3.30 (m, CH2, 2H),
3.34–3.38 (m, H-3), 3.39–3.42 (m, H-5), 3.69–3.77 (m, H-6a), 3.93–4.03 (m, H-6b), 4.29 (q, CH2, 2H),
4.33–4.49 (m, CH2, 2H), 4.57–4.64 (m, H-1), 7.37–7.51 (m, 4H), 7.75–7.76 (m, 2H), 7.92–7.94 (m,
13
1H), 8.43 (s, 1H) ppm. C-NMR (CDCl3, 75 MHz): δ 14.7, 44.8, 60.9, 61.5, 65.6, 69.3, 71.8, 72.2,
74.1, 99.0, 110.7, 122.3, 124.8, 125.4, 129.3, 129.7, 130.1, 130.7, 139.0, 142.5, 156.4, 167.6 ppm.
HRMS (ESI/Q-TOF): m/z calcd for C24H28N2O8 (M+H), 473.1919; found 473.1919.
Ethyl 1-[2′-α-O-D-glucopyranosyl ethyl]-2-o-tolyl-1H-benzimidazole-5-carboxylate (9b). Isolated as
pale yellow semisolid (0.11 g, 66%). IR (film) 3404, 1635, 1265, 744 cm–1; 1H-NMR (CDCl3, 300 MHz):
δ 1.37 (t, CH3, 3H), 2.16 (s, CH3, 3H), 2.71 (d, J = 9.3 Hz, H-4), 3.22–3.26 (m, H-2), 3.27–3.30
(m, CH2, 2H), 3.41–3.43 (m, H-3), 3.44–3.51 (m, H-5), 3.58–3.62 (m, H-6a), 3.80–3.91 (m, H-6b),
4.18–4.28 (m, CH2, 2H) 4.34 (q, CH2, 2H), 4.60 (d, J = 2.7 Hz, H-1), 7.31–7.39 (m, 3H), 7.50–7.57
(m, 2H), 7.98–8.02 (dd, J = 8.4, 1.2 Hz, 1H), 8.47 (d, J = 1.2 Hz, 1H) ppm. 13C-NMR (CDCl3, 75 MHz):
δ 14.7, 20.0, 44.3, 61.2, 61.4, 66.2, 69.6, 71.9, 72.2, 74.1, 99.1, 110.9, 122.4, 124.8, 125.3, 126.5,
129.4, 130.8, 131.0, 138.1, 138.5, 142.5, 155.8, 167.8 ppm. HRMS (ESI/Q-TOF): m/z calcd for
C25H30N2O8 (M+H), 487.2075; found 487.2079.
Ethyl 1-[2'-α-O-D-glucopyranosyl ethyl]-2-p-tolyl-1H-benzimidazole-5-carboxylate (9c). Isolated as
1
pale yellow semisolid (0.10 g, 65%). IR (film) 3411, 1608, 1420, 1265, 740 cm–1; H-NMR (CDCl3,
400 MHz): δ 1.36 (t, J = 7.2 Hz, CH3, 3H), 2.32 (s, CH3, 3H), 2.62 (d, J = 9.2 Hz, H-4), 3.17 (d,
J = 11.2 Hz, H-2), 3.26–3.35 (m, CH2, 2H), 3.36–3.40 (m, H-3), 3.41–3.47 (m, H-5), 3.71–3.73 (m,
H-6a), 3.95–4.03 (m, H-6b), 4.31 (q, J = 7.2 Hz, CH2, 2H), 4.37–4.43 (m, CH2, 1H), 4.47–4.57 (m,
CH2, 1H), 4.61–4.68 (m, H-1), 7.25–7.28 (m, 2H), 7.47 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 8.0 Hz, 2H),
7.94 (d, J = 8.8 Hz, 1H), 8.42 (s, 1H) ppm. 13C-NMR (CDCl3, 75 MHz): δ 14.7, 21.8, 44.8, 60.9, 61.5,
65.6, 69.4, 71.8, 72.2, 74.2, 99.0, 110.7, 122.2, 124.8, 125.4, 126.7, 130.0, 139.1, 141.0, 142.4, 156.6,
167.7 ppm. HRMS (ESI/Q-TOF): m/z calcd for C25H30N2O8 (M+H), 487.2075; found 487.2077.
Ethyl 1-[2'-α-O-D-glucopyranosyl ethyl]-2-p-methoxyphenyl-1H-benzimidazole-5-carboxylate (9d).
1
Isolated as light yellow semisolid (0.06 g, 64%). IR (film) 3402, 1616, 1265, 747 cm–1; H-NMR
(CDCl3, 300 MHz): δ 1.35 (t, CH3, 3H), 2.61 (d, J = 9.0 Hz, H-4), 3.13 (d, J = 10.5 Hz, H-2),

Molecules 2012, 17
9896
3.21–3.30 (m, CH2, 2H), 3.33–3.37 (m, H-3), 3.38–3.46 (m, H-5), 3.72 (s, OCH3, 3H), 3.73–3.79 (m,
H-6a), 3.94–4.08 (m, H-6b), 4.30 (q, CH2, 2H), 4.38–4.57 (m, CH2, 2H), 4.59–4.64 (m, H-1), 6.95 (d,
J = 8.7 Hz, 2H), 7.42 (d, J = 8.4 Hz, 1H), 7.70 (d, J = 8.4 Hz, 2H), 7.91 (d, J = 8.4 Hz, 1H), 8.39
13
(s, 1H) ppm. C-NMR (CDCl3, 75 MHz): δ 14.7, 44.8, 55.7, 60.8, 61.4, 65.5, 69.3, 71.8, 72.2, 74.1,
99.0, 110.5, 114.8, 121.8, 122.0, 124.6, 125.3, 131.6, 139.0, 142.4, 156.4, 161.4, 167.7 ppm. HRMS
(ESI/Q-TOF): m/z calcd for C25H30N2O9 (M+H), 503.2024; found 503.2025.
4. Conclusions
We have described a simple and straightforward synthesis of a series of novel α-O-glucopyranosyl
arylbenzimidazoles using the Appel-Lee reagents. The synthesis of the glycosyl acceptors,
2-arylbenzimidazoles 6a–d, was accomplished in four, high-yielding steps from the inexpensive
precursor 4-fluoro-3-nitrobenzoic acid. Optimised microwave conditions for the reduction and
cyclocondensation steps afforded the 2-arylbenzimidazole aglycones in high yields (82%–94%) and
short reaction times (2–3 min) using reduced amount of solvent. This facile approach would allow
rapid preparation of similar glycosylated benzimidazoles, which will be further investigated under both
conventional and microwave conditions. Bioactivity studies of these glycosyl benzimidazoles will be
reported in due course.
Supplementary Materials
Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/17/8/9887/s1.
Acknowledgments
This work was funded by Universiti Sains Malaysia, RU Grant 1001/PFARMASI/815026, Ministry of
Science, Technology and Innovation (MOSTI) under the R&D initiative Grant No: 09-05-lfn-meb-004,
and Ministry of Higher Education (MoHE), 203/PFARMASI/671159. We are grateful to Mohd Nazri
Ismail and Michael Harvey at Universiti Sains Malaysia (USM) Doping Control Centre for helpful
technical discussions and assistance in providing the HRMS analysis. N.A. thanks USM for the award
of postdoctoral research fellowship.
References
1. Varki, A. Biological roles of oligosaccharides: All of the theories are correct. Glycobiology 1993,
3, 97–130.
2. Gabius, H.-J. Glycans: Bioactive signals decoded by lectins. Biochem. Soc. Trans. 2008, 36,
1491–1496.
3. Varki, A. Nothing in glycobiology makes sense, except in the light of evolution. Cell 2006, 126,
841–845.
4. Unger, F.M. The chemistry of oligosaccharide ligands of selectins: significance for the
development of new immunomodulatory medicines. Adv. Carbohydr. Chem. Biochem. 2001, 57,
207–435.

Molecules 2012, 17
9897
5. Simanek, E.E.; McGarvey, G.J.; Jablonowski, J.A.; Wong, C.-H. Selectin-carbohydrate
interactions: From natural ligands to designed mimics. Chem. Rev. 1998, 98, 833–862.
6. Sato, N.; Oizumi, T.; Kinbara, M.; Sato, T.; Funayama, H.; Sato, S.; Matsuda, K.; Takada, H.;
Sugawara, S.; Endo, Y. Promotion of arthritis and allergy in mice by
aminoglycoglycerophospholipid, a membrane antigen specific to Mycoplasma fermentans.
FEMS Immunol. Med. Microbiol. 2010, 59, 33–41.
7. Kawahito, Y.; Ichinose, S.; Sano, H.; Tsubouchi, Y.; Kohno, M.; Yoshikawa, T.; Tokunaga, D.;
Hojo, T.; Harasawa, R.; Nakano, T. Mycoplasma fermentans glycolipid-antigen as a pathogen of
rheumatoid arthritis. Biochem. Biophys. Res. Commun. 2008, 369, 561–566.
8. Kaila, N.; Thomas, B.E. Design and synthesis of sialyl Lewis(x) mimics as E- and P-selectin
inhibitors. Med. Res. Rev. 2002, 22, 566–601.
9. Chhabra, S.R.; Rahim, A.S.A.; Kellam, B. Recent progress in the design of selectin inhibitors.
Mini-Rev. Med. Chem. 2003, 3, 679–687.
10. Saotome, C.; Kanie, O. Synthetic methodologies. In Carbohydrate-Based Drug Discovery;
Wong, C.-H., Ed.; Wiley: Weinheim, Germany, 2003; Volume 1, pp. 1–36.
11. Ernst, B.; Magnani, J.L. From carbohydrate leads to glycomimetic drugs. Nat. Rev. Drug Discov.
2009, 8, 661–677.
12. Cipolla, L.; La Ferla, B.; Airoldi, C.; Zona, C.; Orsato, A.; Shaikh, N.; Russo, L.; Nicotra, F.
Carbohydrate mimetics and scaffolds: Sweet spots in medicinal chemistry. Future Med. Chem.
2010, 2, 587–599.
13. Chrysina, E.D.; Kosmopoulou, M.N.; Tiraidis, C.; Kardakaris, R.; Bischler, N.; Leonidas, D.D.;
Hadady, Z.; Somsák, L.; Docsa, T.; Gergely, P.; Oikonomakos, N.G. Kinetic and crystallographic
studies on 2-(-D-glucopyranosyl)-5-methyl-1,3,4-oxadiazole, -benzothiazole, and -benzimidazole,
inhibitors of muscle glycogen phosphorylase b. Evidence for a new binding site. Protein Sci.
2005, 14, 873–888.
14. Somsak, L.; Nagy, V.; Hadady, Z.; Docsa, T.; Gergely, P. Glucose analog inhibitors of glycogen
phosphorylases as potential antidiabetic agents: Recent developments. Curr. Med. Chem. 2003, 9,
1177–1189.
15. Hadady, Z.; Tóth, M.; Somsak, L. C-(-D-glucopyranosyl) heterocycles as potential glycogen
phosphorylase inhibitors. ARKIVOC 2004, 140–149.
16. Tóth, M.; Kun, S.; Bokor, É.; Benltifa, M.; Tallec, G.; Vidal, S.; Docsa, T.; Gergely, P.; Somsák, L.;
Praly, J.P. Synthesis and structure-activity relationships of C-glycosylated oxadiazoles as
inhibitors of glycogen phosphorylase. Bioorg. Med. Chem. 2009, 17, 4773–4785.
17. Sachs, G.; Shin, J.M.; Howden, C.W. Review article: the clinical pharmacology of proton pump
inhibitors. Aliment. Pharmacol. Ther. 2006, 23, 2–8.
18. McKellar, Q.A.; Scott, E.W. The benzimidazole anthelmintic agents-a review. J. Vet. Pharmacol.
Ther. 1990, 13, 223–247.
19. Spasov, A.; Yozhitsa, I.; Bugaeva, L.; Anisimova, V. Benzimidazole derivatives: Spectrum of
pharmacological activity and toxicological properties (a review). Pharm. Chem. J. 1999, 33, 232–243.
20. Beaulieu, C.; Wang, Z.; Denis, D.; Greig, G.; Lamontagne, S.; ÓNeill, G.; Slipetz, D.; Wang, J.
Benzimidazoles as new potent and selective DP antagonists for the treatment of allergic rhinitis.
Bioorg. Med. Chem. Lett. 2004, 14, 3195–3199.

Molecules 2012, 17
9898
21. Wan, Y.; Wallinder, C.; Plouffe, B.; Beaudry, H.; Mahalingam, A.K.; Wu, X.; Johansson, B.;
Holm, M.; Botoros, M.; Karlén, A.; et al. Design, synthesis, and biological evaluation of the first
selective nonpeptide AT2 receptor agonist. J. Med. Chem. 2004, 47, 5995–6008.
22. Boiani, M.; González, M. Imidazole and benzimidazole derivatives as chemotherapeutic agents.
Mini-Rev. Med. Chem. 2005, 5, 409–424.
23. Nishida, Y.; Shingu, Y.; Mengfei1, Y.; Fukuda, K.; Dohi, H.; Matsuda, S.; Matsuda, K. An easy
-glycosylation methodology for the synthesis and stereochemistry of mycoplasma α-glycolipid
antigens. Beilstein J. Org. Chem. 2012, 8, 629–639.
24. Murase, H.; Moon, J.H.; Yamauchi, R.; Kato, K.; Kunieda, T.; Yoshikawa, T.; Terao, J.
Antioxidant activity of a novel vitamin E derivative, 2-(-D-glucopyranosyl)methyl-2,5,7,8-
tetramethylchroman-6-ol. Free Radic. Biol. Med. 1998, 24, 217–225.
25. El-Nezhawy, A.O.H.; Gaballah, S.T.; Radwan, M.A.A.; Baiuomy, A.R.; Abdel-Salam, O.M.E.
Structure-based design of benzimidazole sugar conjugates: Synthesis, SAR and in vivo
anti-inflammatory and analgesic activities. Med. Chem. 2009, 5, 558–569.
26. Appel, R. Tertiary Phosphane-Tetrachloromethane, a Versatile Reagent for Chlorination,
Dehydration, and P-N Linkage. Angew. Chem. Int. Ed. 1975, 14, 801–811.
27. Lee, J.; Nolan, T. Sugar Esters: III. New reagent for deoxyhalo sugar preparation. Can. J. Chem.
1966, 44, 1331–1334.
28. Arumugam, N.; Abdul Rahim, A.S.; Abd Hamid, S.; Rosli, M.M.; Fun, H.K. Ethyl 3-amino-4-[(2-
hydroxyethyl)amino]benzoate. Acta Crystallogr. Sect. E: Struct. Rep. Online 2010, 66,
doi:10.1107/S1600536810029077.
29. Yet, L. Five-membered ring systems: With more than one N atom. In Progress in Heterocyclic
Chemistry; Gribble, G.W., Joule J.A.; Eds.; Elsevier: Oxford, UK, 2011; Volume 23, pp. 231–266.
30. Wright, J.B. The Chemistry of the Benzimidazoles. Chem. Rev. 1951, 48, 397–541.
31. Gogoi, P.; Konwar, D. An efficient and one-pot synthesis of imidazolines and benzimidazoles via
anaerobic oxidation of carbon-nitrogen bonds in water. Tetrahedron Lett. 2006, 47, 79–82.
32. Lin, S.; Yang, L. A simple and efficient procedure for the synthesis of benzimidazoles using air as
the oxidant. Tetrahedron Lett. 2005, 46, 4315–4319.
33. Navarrete-Vázquez, G.; Moreno-Diaz, H.; Aguirre-Crespo, F.; León-Rivera, I.; Villalobos-Molina, R.;
Muñoz-Muñiz, O.; Estrada-Soto, S. Design, microwave-assisted synthesis, and spasmolytic
activity of 2-(alkyloxyaryl)-1H-benzimidazole derivatives as constrained stilbene bioisosteres.
Bioorg. Med. Chem. Lett. 2006, 16, 4169–4173.
34. Torres-Gómez, H.; Hernández-Núñez, E.; León-Rivera, I.; Guerrero-Alvarez, J.; Cedillo-Rivera, R.;
Moo-Puc, R.; Argotte-Ramos, R.; Carmen Rodríguez-Gutiérrez, M.D.; Chan-Bacab, M.J.;
Navarrete-Vázquez, G. Design, synthesis and in vitro antiprotozoal activity of benzimidazole-
pentamidine hybrids. Bioorg. Med. Chem. Lett. 2008, 18, 3147–3151.
35. Kappe, C.O.; Dallinger, D. The impact of microwave synthesis on drug discovery. Nat. Rev. Drug
Discov. 2005, 5, 51–63.
36. Arumugam, N.; Abdul Rahim, A.S.; Wahab, H.A.; Goh, J.H.; Fun, H.K. Ethyl 1-(2-
hydroxyethyl)-2-p-tolyl-1H-benzimidazole-5-carboxylate. Acta Crystallogr. Sect. E: Struct. Rep.
Online 2010, 66, o1590–o1591.

Molecules 2012, 17
9899
37. Lindhorst, T. Essentials of Carbohydrate Chemistry and Biochemistry; Wiley-VCH: Weinheim,
Germany, 2007.
38. Demchenko, A.V. 1,2-cis O-Glycosylation: Methods, Strategies, Principles. Curr. Org. Chem.
2003, 7, 35–79.
39. Shingu, Y.; Nishida, Y.; Dohi, H.; Kobayashi, K. An easy access to halide ion-catalytic
-glycosylation using carbon tetrabromide and triphenylphosphine as multifunctional reagents.
Org. Biomol. Chem. 2003, 1, 2518–2521.
40. Nashed, M.A.; Anderson, L. Oligosaccharides from “standardized intermediates.” Synthesis of a
branched tetrasaccharide glycoside related to the blood group B determinant. J. Am. Chem. Soc.
1982, 104, 7282–7286.
41. Cromer, R.; Spohr, U.; Khare, D.P.; LePendu, J.; Lemieux, R.U. Molecular recognition XII.
The binding of the H human blood group determinants and congeners by a lectin of
Galactia tenuiflora. Can. J. Chem. 1992, 70, 1511–1530.
42. Shingu, Y.; Miyachi, A.; Miura, Y.; Kobayashi, K.; Nishida, Y. One-pot -glycosylation pathway
via the generation in situ of alpha-glycopyranosyl imidates in N,N-dimethylformamide.
Carbohydr. Res. 2005, 340, 2236–2244.
Sample Availability: Samples of the compounds 8a–d and 9a–d are available from the authors.
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).